Johnson & Johnson (NYSE:JNJ) Shares Sold by Atria Investments Inc

Atria Investments Inc decreased its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 0.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 206,796 shares of the company’s stock after selling 585 shares during the period. Atria Investments Inc’s holdings in Johnson & Johnson were worth $32,209,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. State Street Corp boosted its stake in Johnson & Johnson by 1.1% during the 2nd quarter. State Street Corp now owns 141,833,756 shares of the company’s stock valued at $23,476,323,000 after acquiring an additional 1,568,633 shares during the last quarter. Moneta Group Investment Advisors LLC lifted its position in Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Geode Capital Management LLC lifted its position in Johnson & Johnson by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 49,697,798 shares of the company’s stock valued at $8,203,608,000 after purchasing an additional 990,298 shares during the last quarter. Morgan Stanley lifted its position in Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. Finally, Capital International Investors lifted its position in Johnson & Johnson by 62.7% in the 2nd quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock valued at $4,605,627,000 after purchasing an additional 10,724,110 shares during the last quarter. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research analyst reports. UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the company from $167.00 to $180.00 in a research note on Friday, December 1st. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, November 17th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Finally, Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $170.00 to $163.00 in a research note on Wednesday, December 13th. Eight analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $176.14.

Read Our Latest Stock Report on Johnson & Johnson

Johnson & Johnson Price Performance

NYSE JNJ opened at $157.98 on Thursday. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $380.30 billion, a PE ratio of 11.44, a price-to-earnings-growth ratio of 2.62 and a beta of 0.53. The company has a 50 day moving average price of $158.20 and a two-hundred day moving average price of $159.04. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.28 by $0.01. The firm had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The business’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.35 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 3.01%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 34.47%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.